FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
This article was originally published in The Rose Sheet
Executive Summary
In a Feb. 12 warning letter, just the descriptors for two L’Oreal/La Roche-Posay products – a “Localized Redness Intensive Serum” and “Concentrated Dark Spot Correcting Serum” – are cited by FDA as evidence that the products are intended for use as drugs. The warning raises questions about the viability of those categories for cosmetics firms intent on staying off FDA’s radar.
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: